RE:Here's the thing We need real numbers in order to deem the value of this company. For the moment the share trades between 13-14 cents, but if we had more information the range could be 40-50 or 120-130.
Nevertheless, even though the last NR fuels the share price it's good to know that we're advancing on anti-viral which is a huge market.
The COVID application is not very important any longer from a health perspective, but still high profile since everyone can relate. If successful, the anti-viral segment could be very successful from a financial perspective. Not today, not tomorrow but at least included in an exit deal.